Dr. Vokes on Pembrolizumab Plus Chemotherapy and Radiation in Lung Cancer

Everett Vokes, MD
Published: Monday, Aug 14, 2017



Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses pembrolizumab (Keytruda) plus chemotherapy and radiation therapy in patients with lung cancer.

According to Vokes, pembrolizumab, chemotherapy, and radiation is a relevant treatment option for patients with lung cancer. There was a trial investigating this for patients with nonsquamous non-small cell lung cancer (NSCLC), which accrued 500 patients. It showed no difference in progression-free survival and overall survival, states Vokes.
 


Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses pembrolizumab (Keytruda) plus chemotherapy and radiation therapy in patients with lung cancer.

According to Vokes, pembrolizumab, chemotherapy, and radiation is a relevant treatment option for patients with lung cancer. There was a trial investigating this for patients with nonsquamous non-small cell lung cancer (NSCLC), which accrued 500 patients. It showed no difference in progression-free survival and overall survival, states Vokes.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Community Practice Connections™: 4th Annual Miami Lung Cancer Conference®Jun 30, 20187.0
Publication Bottom Border
Border Publication
x